Income statement
GBP
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 673M | 669M | 690M | 593M | 574M |
| Gross Profit | 673M | 179M | 239M | 226M | 232M |
| Operating Income | 42M | 6M | 41M | 57M | 62M |
| EBITDA | 94M | 74M | 88M | 80M | 82M |
| Net Income | 19M | 8M | 33M | 41M | 47M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$31.07
+0.00% today
1Y Change
+19.43%
Window
Jun 26, 2025 → Jun 22, 2026
Coverage: 254 bars · Jun 26, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genus plc (GENSF) is a Healthcare stock with a market cap of $1.56B and listed on OTC. The stock last traded around $31.07 and up 19.4% across the available one-year price window (Jun 26, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of +0.6%, EPS growth of +108.3%, a dividend yield of 1.4%. What stands out right now is revenue +0.6%, EPS +108.3%, free cash flow +852.9% with operating margin 9.8% and ROIC 6.0%. The dividend is present but secondary, with a yield around 1.4%. Valuation already assumes a fairly strong business story at P/E 32.6 and price/sales 2.3. Stock Foundry combines GENSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GENSF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GENSF Max Drawdown
-16.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for GENSF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$574.3M
-3.2% YoY
FY Net Income
$47.3M
+15.6% YoY
Free Cash Flow
$38.8M
+597.4% YoY
Revenue Growth
+0.6%
EPS Growth
+108.3%
Gross Margin
100.1%
Net Margin
7.1%
Income statement
GBP
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 673M | 669M | 690M | 593M | 574M |
| Gross Profit | 673M | 179M | 239M | 226M | 232M |
| Operating Income | 42M | 6M | 41M | 57M | 62M |
| EBITDA | 94M | 74M | 88M | 80M | 82M |
| Net Income | 19M | 8M | 33M | 41M | 47M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
GBP
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 48M | 43M | 36M | 39M | 46M |
| Total Assets | 899M | 1.0B | 1.0B | 1.0B | 851M |
| Total Liabilities | 423M | 485M | 440M | 446M | 354M |
| Shareholder Equity | 476M | 548M | 569M | 579M | 498M |
| Total Debt | 266M | 291M | 232M | 224M | 152M |
| Net Debt | 218M | 249M | 196M | 185M | 106M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
68M
+96.8% YoY
Capital Expenditures
29M
+31.8% YoY
Free Cash Flow
39M
+597.4% YoY
Key ratios
Gross Margin
100.1%
Operating Margin
9.8%
Net Margin
7.1%
ROE
9.7%
Debt / Equity
0.55x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.